|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 25 Massachusetts Avenue, NW |
Address2 | Suite 610 |
| City | Washingon |
State | DC |
Zip Code | 20001-1430 |
Country | USA |
3. Principal place of business (if different than line 2)
| City | Schaumburg |
State | IL |
Zip Code | 60173 |
Country | USA |
|
5. Senate ID# 10445-12
|
||||||||
|
6. House ID# 338760000
|
||||||||
| TYPE OF REPORT | 8. Year | 2023 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: MS. KATHERINE O. ORRICO |
Date | 7/20/2023 4:37:32 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
S.230/H.R. 834: To support rural residency training funding that is equitable for all States
S.470/H.R.977, Patient Access to Higher Quality Health Care Act: To repeal changes made by health care reform laws to the Medicare exception to the prohibition on certain physician referrals for hospitals.
H.R.751, Fair Access in Residency (FAIR) Act: To encourage more equitable treatment of osteopathic and allopathic candidates in the residency application and review process.
H.R.2389, Resident Physician Shortage Reduction Act: To provide for the distribution of additional residency positions
H.R. 2474, Strengthening Medicare for Patients and Providers Act: To provide an update to a single conversion factor under the Medicare physician fee schedule that is based on the Medicare economic index.
H.R. 2713, the Improving Care and Access to Nurses Act: To increase access to services provided by advanced practice registered nurses under the Medicare and Medicaid programs
H.R.4402, Sunshine Act of 2023:To clarify manufacturer transparency reporting requirements for certain transfers used for educational purposes
No bill: Medicare physician payment reforms including modifications to budget neutrality and the Quality Payment Programm
No bill: Prior authorization reform legislation in Medicare Advantage
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Katherine |
Orrico |
|
|
|
Adrienne |
Mortimer |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
S. 652/H.R. 2630, Safe Step Act: To require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for any medication step therapy protocol
S.704/H.R 1202, Resident Education Deferred Interest (REDI) Act: To provide for interest-free deferment on student loans for borrowers serving in a medical or dental internship or residency program
S. 801/H.R.1616, Comprehensive Access to Resources and Education (CARE) For Long COVID Act: To address research on, and improve access to, supportive services for individuals with Long COVID
S. 1001/H.R. 1843, Telehealth Expansion: To permanently extend the exemption for telehealth services from certain high deductible health plan rule
S.1026, Gun Violence Prevention Research Act: To authorize the appropriation of funds to the Centers for Disease Control and Prevention for conducting or supporting research on firearms safety or gun violence prevention
S. 1653, the Prevent Blood Loss with Emergency Equipment Devices (BLEEDing) Act: To establish a program to award grants to State, local, and Tribal governments to purchase and distribute anti-blood loss supplies for use in a medical emergency.
S.Res.229/H.Res.355Supporting the designation of May 2023 as National Brain Tumor Awareness Month
S.Res.257/ H.Res.425Supporting the designation of July 19, 2023, as Glioblastoma Awareness Day
H.R.2761, Specialty Physicians Advancing Rural Care (SPARC) Act: To authorize a loan repayment program to encourage specialty medicine physicians to serve in rural communities experiencing a shortage of specialty medicine physicians
HR 2819, Good Samaritan Health Professionals Act: To limit the liability of health care professionals who volunteer to provide health care services in response to a disaster.
H.R.3887, Childrens Hospital GME Support Reauthorization Act: To reauthorize the program of payments to childrens hospitals that operate graduate medical education programs
No bill: Reintroduction of the Accessible Care by Curbing Excessive lawSuitS (ACCESS) Act: Comprehensive medical liability reform
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Katherine |
Orrico |
|
|
|
Adrienne |
Mortimer |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
S.895/H.R. 902, Ellies Law: Funding for comprehensive research at the National Institute of Neurological Disorders and Stroke on unruptured intracranial aneurysms.
S.1026/H.R. 2390, Gun Violence Prevention Research Act: To authorize the appropriation of funds to the Centers for Disease Control and Prevention for conducting or supporting research on firearms safety or gun violence prevention.
S. 1624/H.R. 3391, Gabriella Miller Kids First Research Act 2.0: To require certain civil penalties to be transferred to a fund through which amounts are made available for the Gabriella Miller Kids First Pediatric Research Program at the National Institutes of Health.
No Bill: Funding for Neglected Surgical Conditions within the State, Foreign Operations, and Related Programs (SFOPS) Appropriations Report for Fiscal Year (FY) 2024
No Bill: Funding for the U.S. Centers for Disease Control and Prevention, the National Institutes of Health, and National Institute of Justice to conduct public health research into firearm morbidity and mortality prevention.
No Bill: Funding for MISSION ZERO military/civilian trauma preparedness program
No Bill: Funding for the Pediatric Subspecialty Loan Repayment Program
No Bill: Increased funding for the National Institutes of Health for biomedical research.
No Bill: Funding for the Pediatric Device Consortia Grant Program at the Office of Orphan Products Development at the Food and Drug Administration.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Katherine |
Orrico |
|
|
|
Adrienne |
Mortimer |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |